Shneyderman Mark, Freid Hannah, Kohler David, Peraza Jellyana, Haskey Natasha, Abbott Erin, Kornbluth Asher, Raman Maitreyi, Gold Stephanie
Icahn School of Medicine at Mount Sinai Hospital, New York, New York.
Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York.
Gastroenterol Hepatol (N Y). 2024 Dec;20(12):712-722.
Increasing evidence has linked obesity to complications of inflammatory bowel disease (IBD); however, data are limited on the efficacy and impact of weight management strategies on the disease course. There are a strikingly limited number of interventional studies on weight management in patients with IBD, and the recent nutrition and IBD guidelines published in the United States do not mention weight management strategies. Overweight and obesity management in patients with IBD should follow a stepwise approach to assessment and treatment, including lifestyle modification, anti-obesity medications such as glucagon-like peptide-1 agonists, endobariatric procedures, and bariatric surgery (if deemed appropriate). This article reviews the management of overweight and obesity in patients with IBD, examines the efficacy of currently available interventions and their impact on the IBD course, and proposes a stepwise approach to the assessment and treatment of overweight or obesity for the IBD provider.
越来越多的证据表明肥胖与炎症性肠病（IBD）的并发症有关；然而，关于体重管理策略对疾病进程的疗效和影响的数据有限。针对IBD患者体重管理的干预性研究数量极为有限，而且美国最近发布的营养与IBD指南并未提及体重管理策略。IBD患者的超重和肥胖管理应遵循逐步评估和治疗的方法，包括生活方式改变、抗肥胖药物（如胰高血糖素样肽-1激动剂）、内镜减重手术以及减重手术（如认为合适）。本文回顾了IBD患者超重和肥胖的管理，研究了现有干预措施的疗效及其对IBD病程的影响，并为IBD医疗服务提供者提出了超重或肥胖评估和治疗的逐步方法。
